Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1981 2
1982 1
1983 2
1984 1
1985 2
1988 1
1989 5
1990 6
1991 1
1992 5
1993 3
1994 4
1995 3
1996 3
1997 3
1998 3
1999 7
2000 4
2001 2
2002 10
2003 9
2004 2
2005 8
2006 9
2007 4
2008 4
2009 6
2010 7
2011 7
2012 7
2013 6
2014 10
2015 3
2016 6
2017 1
2018 1
2019 3
2020 2
2021 2
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Cortes J, et al. Among authors: bougnoux p. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. Lancet. 2011. PMID: 21376385 Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
KCa and Ca(2+) channels: the complex thought.
Guéguinou M, Chantôme A, Fromont G, Bougnoux P, Vandier C, Potier-Cartereau M. Guéguinou M, et al. Among authors: bougnoux p. Biochim Biophys Acta. 2014 Oct;1843(10):2322-33. doi: 10.1016/j.bbamcr.2014.02.019. Epub 2014 Mar 6. Biochim Biophys Acta. 2014. PMID: 24613282 Free article. Review.
Diet, cancer, and the lipidome.
Bougnoux P, Giraudeau B, Couet C. Bougnoux P, et al. Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):416-21. doi: 10.1158/1055-9965.EPI-05-0546. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16537692 Free PMC article. Review.
Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.
Jaffrès PA, Gajate C, Bouchet AM, Couthon-Gourvès H, Chantôme A, Potier-Cartereau M, Besson P, Bougnoux P, Mollinedo F, Vandier C. Jaffrès PA, et al. Among authors: bougnoux p. Pharmacol Ther. 2016 Sep;165:114-31. doi: 10.1016/j.pharmthera.2016.06.003. Epub 2016 Jun 8. Pharmacol Ther. 2016. PMID: 27288726 Review.
Targeting SKCa channels in cancer: potential new therapeutic approaches.
Girault A, Haelters JP, Potier-Cartereau M, Chantôme A, Jaffrés PA, Bougnoux P, Joulin V, Vandier C. Girault A, et al. Among authors: bougnoux p. Curr Med Chem. 2012;19(5):697-713. doi: 10.2174/092986712798992039. Curr Med Chem. 2012. PMID: 22204342 Review.
159 results